Central role and mechanisms of β-cell dysfunction and death in friedreich ataxia-associated diabetes

Annals of Neurology

Volumn 72, Issue 6, 2012, Pages 971-982

  Cnop, Miriam ^a,b   Igoillo Esteve, Mariana ^a   Rai, Myriam ^a   Begu, Audrey ^c   Serroukh, Yasmina ^a   Depondt, Chantal ^a   Musuaya, Anyishai E ^a   Marhfour, Ihsane ^a   Ladrière, Laurence ^a   Moles Lopez, Xavier ^a   Lefkaditis, Dionysios ^d   Moore, Fabrice ^a   Brion, Jean Pierre ^a   Cooper, J Mark ^e   Schapira, Anthony H V ^e   Clark, Anne ^f   Koeppen, Arnulf H ^g   Marchetti, Piero ^h   Pandolfo, Massimo ^a   Eizirik, Décio L ^a   Féry, Françoise ^b   more..

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Digital Image Analysis in Pathology (DIAPATH)   (Belgium)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g STRATTON VA MEDICAL CENTER   (United States)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FRATAXIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ABDOMINAL FAT; ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; AUTOPSY; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FRIEDREICH ATAXIA; GLUCOSE TOLERANCE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFECT; RAT; RNA INTERFERENCE; TRINUCLEOTIDE REPEAT;

ADIPOSE TISSUE; ADULT; ANIMALS; BODY FAT DISTRIBUTION; DIABETES MELLITUS; ENERGY METABOLISM; FAMILY HEALTH; FEMALE; FLOW CYTOMETRY; FRIEDREICH ATAXIA; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; IRON-BINDING PROTEINS; LINEAR MODELS; MALE; MIDDLE AGED; RATS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84871957143     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23698     Document Type: Article

References (61)

1. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996; 335: 1169-1175. (Pubitemid 26339770)
2. Schulz JB, Boesch S, Burk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 2009; 5: 222-234.
3. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996; 271: 1423-1427. (Pubitemid 26089479)
4. Pandolfo M,. The molecular basis of Friedreich ataxia. Adv Exp Med Biol 2002; 516: 99-118. (Pubitemid 36337738)
5. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006; 2: 551-558. (Pubitemid 44413238)
6. Koeppen AH,. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011; 303: 1-12.
7. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997; 6: 1771-1780. (Pubitemid 27460350)
8. Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996; 59: 554-560. (Pubitemid 26269033)
9. Bulteau AL, O'Neill HA, Kennedy MC, et al. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004; 305: 242-245. (Pubitemid 38886737)
10. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997; 17: 215-217.
11. Tsai CL, Barondeau DP,. Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex. Biochemistry 2010; 49: 9132-9139.
12. Gakh O, Park S, Liu G, et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet 2006; 15: 467-479. (Pubitemid 43159898)
13. Gonzalez-Cabo P, Vazquez-Manrique RP, Garcia-Gimeno MA, et al. Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum Mol Genet 2005; 14: 2091-2098. (Pubitemid 41418009)
14. Chantrel-Groussard K, Geromel V, Puccio H, et al. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet 2001; 10: 2061-2067. (Pubitemid 32998818)
15. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997; 276: 1709-1712. (Pubitemid 27421980)
16. Lin MT, Beal MF,. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795. (Pubitemid 44622683)
17. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-1142. (Pubitemid 36583097)
18. Filla A, DeMichele G, Caruso G, et al. Genetic data and natural history of Friedreich's disease: a study of 80 Italian patients. J Neurol 1990; 237: 345-351. (Pubitemid 20332043)
19. Finocchiaro G, Baio G, Micossi P, et al. Glucose metabolism alterations in Friedreich's ataxia. Neurology 1988; 38: 1292-1296.
20. Shapcott D, Melancon S, Butterworth RF, et al. Glucose and insulin metabolism in Friedreich's ataxia. Can J Neurol Sci 1976; 3: 361-364. (Pubitemid 8067192)
21. Bird TD, Turner JL, Sumi SM, et al. Abnormal function of endocrine pancreas and anterior pituitary in Friedreich's ataxia. Studies in a family. Ann Intern Med 1978; 88: 478-481. (Pubitemid 8330292)
22. Schoenle EJ, Boltshauser EJ, Baekkeskov S, et al. Preclinical and manifest diabetes mellitus in young patients with Friedreich's ataxia: no evidence of immune process behind the islet cell destruction. Diabetologia 1989; 32: 378-381. (Pubitemid 19171843)
23. Tolis G, Mehta A, Andermann E, et al. Friedreich's ataxia and oral glucose tolerance: I. The effect of ingested glucose on serum glucose and insulin values in homozygotes, obligate heterozygotes and potential carriers of the Friedreich's ataxia gene. Can J Neurol Sci 1980; 7: 397-400. (Pubitemid 11205158)
24. Coppola G, Marmolino D, Lu D, et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich's ataxia. Hum Mol Genet 2009; 18: 2452-2461.
25. Fantus IG, Janjua N, Senni H, et al. Glucose intolerance in first-degree relatives of patients with Friedreich's ataxia is associated with insulin resistance: evidence for a closely linked inherited trait. Metabolism 1991; 40: 788-793.
26. Khan RJ, Andermann E, Fantus IG,. Glucose intolerance in Friedreich's ataxia: association with insulin resistance and decreased insulin binding. Metabolism 1986; 35: 1017-1023. (Pubitemid 17186303)
27. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A 1999; 96: 11492-11495. (Pubitemid 29487408)
28. Vorgerd M, Schols L, Hardt C, et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 2000; 10: 430-435. (Pubitemid 30433814)
29. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671. (Pubitemid 38364625)
30. Hebinck J, Hardt C, Schols L, et al. Heterozygous expansion of the GAA tract of the X25/frataxin gene is associated with insulin resistance in humans. Diabetes 2000; 49: 1604-1607.
31. Ristow M, Giannakidou E, Hebinck J, et al. An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich's ataxia) gene. Diabetes 1998; 47: 851-854. (Pubitemid 28201821)
32. Dalgaard LT, Hansen T, Urhammer SA, et al. Intermediate expansions of a GAA repeat in the frataxin gene are not associated with type 2 diabetes or altered glucose-induced β-cell function in Danish Caucasians. Diabetes 1999; 48: 914-917. (Pubitemid 29153095)
33. Holmkvist J, Almgren P, Parikh H, et al. Haplotype construction of the FRDA gene and evaluation of its role in type II diabetes. Eur J Hum Genet 2005; 13: 849-855. (Pubitemid 40946084)
34. Miranda CJ, Santos MM, Ohshima K, et al. Frataxin knockin mouse. FEBS Lett 2002; 512: 291-297. (Pubitemid 34164497)
35. Ristow M, Mulder H, Pomplun D, et al. Frataxin deficiency in pancreatic islets causes diabetes due to loss of β cell mass. J Clin Invest 2003; 112: 527-534. (Pubitemid 38056337)
36. Cossee M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000; 9: 1219-1226. (Pubitemid 30248608)
37. Bergman RN, Prager R, Volund A, et al. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79: 790-800. (Pubitemid 17050904)
38. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-1672. (Pubitemid 23318125)
39. Frayn KN,. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634. (Pubitemid 13044099)
40. Ellis KJ,. Human body composition: in vivo methods. Physiol Rev 2000; 80: 649-680. (Pubitemid 30164946)
41. Blanc S, Schoeller D, Kemnitz J, et al. Energy expenditure of rhesus monkeys subjected to 11 years of dietary restriction. J Clin Endocrinol Metab 2003; 88: 16-23. (Pubitemid 36115135)
42. Ravussin E, Bogardus C,. Relationship of genetics, age, and physical fitness to daily energy expenditure and fuel utilization. Am J Clin Nutr 1989; 49: 968-975. (Pubitemid 19136571)
43. Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005; 64: 1261-1262.
44. Schwab RS, England AC,. Projection technique for evaluating surgery in Parkinson's disease. In:, Gillingham FJ, Donaldson IML, eds. Third symposium on Parkinson's disease. Edinburgh, UK: Livingstone, 1969: 152-157.
45. Pandolfo M,. Friedreich ataxia: detection of GAA repeat expansions and frataxin point mutations. Methods Mol Med 2006; 126: 197-216.
46. Del Guerra S, D'Aleo V, Gualtierotti G, et al. Evidence for a role of frataxin in pancreatic islets isolated from multi-organ donors with and without type 2 diabetes mellitus. Horm Metab Res 2012; 44: 471-475.
47. Fantus IG, Seni MH, Andermann E,. Evidence for abnormal regulation of insulin receptors in Friedreich's ataxia. J Clin Endocrinol Metab 1993; 76: 60-63. (Pubitemid 23027553)
48. Petersen KF, Dufour S, Shulman GI,. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2005; 2: e233.
49. Befroy DE, Petersen KF, Dufour S, et al. Increased substrate oxidation and mitochondrial uncoupling in skeletal muscle of endurance-trained individuals. Proc Natl Acad Sci U S A 2008; 105: 16701-16706.
50. Bullough RC, Gillette CA, Harris MA, et al. Interaction of acute changes in exercise energy expenditure and energy intake on resting metabolic rate. Am J Clin Nutr 1995; 61: 473-481.
51. Sleigh A, Raymond-Barker P, Thackray K, et al. Mitochondrial dysfunction in patients with primary congenital insulin resistance. J Clin Invest 2011; 121: 2457-2461.
52. Apabhai S, Gorman GS, Sutton L, et al. Habitual physical activity in mitochondrial disease. PLoS One 2011; 6: e22294.
53. Eizirik DL, Cardozo AK, Cnop M,. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008; 29: 42-61. (Pubitemid 351252746)
54. Cnop M, Vidal J, Hull RL, et al. Progressive loss of β-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007; 30: 677-682. (Pubitemid 46354352)
55. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794. (Pubitemid 29536364)
56. Lyssenko V, Almgren P, Anevski D, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005; 54: 166-174. (Pubitemid 40105109)
57. Kriketos AD, Carey DG, Jenkins AB, et al. Central fat predicts deterioration of insulin secretion index and fasting glycaemia: 6-year follow-up of subjects at varying risk of type 2 diabetes mellitus. Diabet Med 2003; 20: 294-300. (Pubitemid 36606122)
58. Handschin C, Choi CS, Chin S, et al. Abnormal glucose homeostasis in skeletal muscle-specific PGC-1α knockout mice reveals skeletal muscle-pancreatic β cell crosstalk. J Clin Invest 2007; 117: 3463-3474. (Pubitemid 350097002)
59. Drucker DJ,. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
60. Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006; 4: 391-406. (Pubitemid 44752565)
61. Cunha DA, Ladrière L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic β-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 2009; 58: 2851-2862